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Breast cancer progression, treatment resistance,
and relapse are thought to originate from a small
population of tumor cells, breast cancer stem cells
(BCSCs). Identification of factors critical for BCSC
function is therefore vital for the development of
therapies. Here, we identify the arginine methyltrans-
ferase PRMT5 as a key in vitro and in vivo regulator of
BCSC proliferation and self-renewal and establish
FOXP1, a winged helix/forkhead transcription factor,
as a critical effector of PRMT5-induced BCSC
function. Mechanistically, PRMT5 recruitment to the
FOXP1 promoter facilitates H3R2me2s, SET1 recruit-
ment, H3K4me3, and gene expression. Our findings
are clinically significant, as PRMT5 depletion within
established tumor xenografts or treatment of pa-
tient-derived BCSCswith a pre-clinical PRMT5 inhib-
itor substantially reduces BCSC numbers. Together,
our findings highlight the importance of PRMT5 in
BCSCmaintenance and suggest that small-molecule
inhibitors of PRMT5 or downstream targets could be
an effective strategy eliminating this cancer-causing
population.
INTRODUCTION
Despite advances in early screening strategies and development
of treatments tailored to specific molecular subtypes, breast
cancer is still a disease associated with significant morbidity3498 Cell Reports 21, 3498–3513, December 19, 2017 ª 2017 The A
This is an open access article under the CC BY license (http://creativeand mortality. A major contributing factor is resistance to first-
line therapy and disease recurrence coupled with metastatic
dissemination. Emerging research suggests that the main phe-
nomenon contributing to this is the presence of ‘‘tumor-initiating
cells,’’ a small population of cells in the bulk tumor mass that is
thought to be responsible for tumor initiation, maintenance, het-
erogeneity, and drug resistance. Because these cells share
many biological traits with normal stem cells, they are often
referred to as breast cancer stem cells (BCSCs). BCSCs can
asymmetrically divide, producing one stem cell (self-renewal)
and one daughter progenitor cell, which is the root of the hierar-
chy that defines cancer heterogeneity. Importantly, these cells
have slow rates of division, high expression of drug efflux pumps,
and high capacity for DNA repair (Holohan et al., 2013) and are
thus relatively drug resistant. Therefore, although BCSCs repre-
sent only a small proportion of the bulk tumor, they are of major
clinical importance. Given the failure of current treatments, iden-
tifying factors that are critical for BCSC function is vital for the
development of novel therapies.
In the breast, cancer stem cells (CSCs) aremolecularly defined
as ESA+CD24lowCD44+ (Al-Hajj et al., 2003; Fillmore and Kuper-
wasser, 2008). Transplantation of as few as 1,000 patient-
derived ESA+CD24lowCD44+ cells enabled reconstitution of a
heterogeneous tumor phenotypically resembling the original
tumor. Moreover, ESA+CD24lowCD44+ cells isolated from xeno-
grafts could undergo multiple rounds of serial transfer in mice
(Al-Hajj et al., 2003). Thus, the ESA+CD24lowCD44+ lineage has
considerable proliferative and repopulating potential and has
been extensively used to isolate cells with increased tumorige-
nicity, defining the breast tumor-initiating population. This
phenomenon can also be recapitulated in vitro; culturing of
patient-derived or breast cancer cell lines in suspension asuthors.
commons.org/licenses/by/4.0/).
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mammospheres enriches for tumor-initiating cells that generate
in vivo tumor growth 1,000 times more potently than monolayer-
derived cells (Ponti et al., 2005).
Post-translational modification of histone tails leading to
changes in chromatin composition and configuration is a
principal component of epigenetic-mediated gene expression.
Recently, there has been a growing appreciation that histone-
modifying enzymes are responsible for promoting gene expres-
sion in CSCs that facilitates cellular plasticity between cancer
and non-cancer stem cell-like phenotypes (Feinberg et al.,
2016; Harrison et al., 2010; Mun˜oz et al., 2012). This is also
true in the breast, in which deregulated histone lysine methyl-
ation contributes to BCSC function and aggressive disease
(Chang et al., 2011; Wu et al., 2013). In contrast, very little is
understood about the contribution of arginine methylation.
Protein arginine methyltransferases (PRMTs) catalyze mono-
and dimethylation of the guanidino group of the arginine residue
using S-adenosyl methionine (SAM) as amethyl donor. Dimethy-
lation can occur asymmetrically (asymmetric dimethylarginine
[ADMA]), with two methyl groups placed onto one of the terminal
nitrogen atoms of the guanidino group, or symmetrically (sym-
metric dimethylarginine [SDMA]), whereby one methyl group is
placed onto each of the terminal nitrogen atoms. Recently
PRMT5, the main symmetric arginine dimethyltransferase in
mammalian cells, has been increasingly associated with stem-
ness. PRMT5 maintains embryonic stem cell (ESC) pluripotency
by upregulating NANOG and OCT4 expression (Tee et al., 2010),
promotes somatic cell reprogramming (Goyal et al., 2013; Naga-
matsu et al., 2011), and is required for the homeostasis of adult
stem cells (Liu et al., 2015; Zhang et al., 2015). Notably, PRMT5
can drive or repress gene expression according to the modified
histone residue; histone H3R2me2s drives H3K4me3 and gene
expression, while methylation of H2AR3, H4R3, and H4R8
represses gene activation (Di Lorenzo and Bedford, 2011;
Migliori et al., 2012). Given the parallels between normal stem
cell function, somatic cell reprogramming, and CSCs, these find-
ings imply that PRMT5 may be an important regulator of CSCs.
Indeed, PRMT5 has been shown to contribute to leukemic and
glioblastoma stem cell function (Banasavadi-Siddegowda
et al., 2017; Jin et al., 2016). Regarding the breast, very few
studies have addressed the potential pro-tumorigenic role of
PRMT5, despite high PRMT5 expression being associated with
breast cancer progression, aggressive disease, and poor prog-
nosis (Chen et al., 2017; Powers et al., 2011; Yang et al.,
2015). Using a systematic in vitro and in vivo approach to analyze
the contribution of PRMT5 to BCSC function, we found thatFigure 1. PRMT5 Is Preferentially Expressed in BCSC-Enriched Cell Pop
(A and B) Immunoblot of PRMT5 and PRMT1 levels in (A) anoikis-resistant and (
below.
(C) Immunoblot of MCF7 cells expressing a non-targeting shRNA or two inde
shPRMT1[2], shPRMT5[1] and shPRMT5[2]) (top). Mammosphere assay of cells
(D) Mammosphere assay of T47D ER+ breast cancer cells expressing shCTRL, s
mosphere-forming unit.
(E) ALDEFLUOR assay of T47D shCTRL, shPRMT5(1), or shPRMT5(2). Percenta
(F) Immunoblot of PRMT5, MEP50, and pan-symmetric dimethylarginine (SDMA) i
(PRMT5-WT or PRMT5 G367A/R368A) and/or MEP50.
(G) Mammosphere assay of cells overexpressing PRMT5 and/or MEP50.
All data are mean ± SEM, nR 3.
3500 Cell Reports 21, 3498–3513, December 19, 2017PRMT5 depletion in established estrogen receptor (ER)+ xeno-
grafts not only reduced tumor growth but substantially reduced
the proportion of BCSCs after serial transplantation. Signifi-
cantly, treatment of BCSCs isolated from patient-derived tumors
with a pre-clinical PRMT5 small-molecule inhibitor substantially
reduced tumor-initiating potential. Our results thus demonstrate
the importance of PRMT5-mediated arginine methylation for
BCSC function and tumor initiation and imply that drug targeting
of this pathway could have significant patient benefit by eradi-
cating the cell population responsible for drug resistance and
recurrence.
RESULTS
PRMT5, but Not PRMT1, Is Functionally Required for
In Vitro BCSC Function in ER+ Breast Cancers
PRMT1 and PRMT5 have been increasingly linked to stem cell
function in normal and cancer cells (Banasavadi-Siddegowda
et al., 2017; Blanc et al., 2017; Jin et al., 2016; Liu et al., 2015;
Zhang et al., 2015) and breast cancer pathogenesis (Baldwin
et al., 2012; Chen et al., 2017; Goulet et al., 2007; Powers
et al., 2011; Yang et al., 2015). Whilst depletion of PRMT5
reduces the proliferation of bulk MCF7 breast cancer cells (Fig-
ure S1A; Scoumanne et al., 2009), no study has yet examined
whether PRMT1 and PRMT5 also regulate the BCSC population.
To address this, we exploited the fact that breast cancer cell
lines possess a small population of cells that molecularly and
functionally behave as cancer stem cells (Harrison et al., 2010;
Ponti et al., 2005). Two approaches were used to isolate this
population: flow cytometry gating on ESA+CD24lowCD44+ (Fig-
ure S1B) and the isolation of viable MCF7 cells after 16 hr sus-
pension culture on poly-HEMA-coated plates to prevent cell
attachment (Figure S1C). These anoikis-resistant (AR) cells are
significantly enriched in stem cell markers compared with their
monolayer counterpart and have tumor-initiating capacities
(Harrison et al., 2010). Although PRMT1 levels remained the
same, PRMT5 expression was significantly elevated within the
AR or BCSC population (Figures 1A and 1B). To investigate
the significance of this, we generated two PRMT1 and PRMT5-
knockdown MCF7 cell lines each expressing distinct short
hairpin RNA (shRNA) sequences (shPRMT1[1] and shPRMT1
[2]; shPRMT5[1] and shPRMT5[2]; Figure 1C) and analyzed their
ability to form mammospheres, a measure of the number and
proliferative potential of tumor-initiating cells in vitro (Ponti
et al., 2005). Depletion of either PRMT1 or PRMT5 reduced pri-
mary mammosphere formation, indicative of either reducedulations and Is Required for Self-Renewal of ER+Breast Cancer Cells
B) ESA+CD24lowCD44+ BCSC-enriched populations of MCF7 cells, quantified
pendent shRNAs targeting either PRMT1 or PRMT5 (shCTRL, shPRMT1[1],
after PRMT1 or PRMT5 depletion (bottom).
hPRMT5(1), or shPRMT5(2). PRMT5 depletion is shown (above). MFU, mam-
ge ALDEFLUOR+ cells is quantified (right).
n MCF7 cells engineered to express wild-type or enzymatically inactive PRMT5
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C
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stem cell/progenitor proliferation or a reduction in the number
of tumor-initiating cells, but only depletion of PRMT5 led to a
further reduction in secondary mammospheres, suggesting
self-renewal defects (Figure 1C). Thus, it appears that although
both PRMT1 and PRMT5 are required for BCSC proliferation
and production of progenitor cells, only PRMT5 is required for
BCSC self-renewal. To validate these findings, we repeated
these experiments in a second ER+ breast cancer cell line,
T47D (Figure 1D), and analyzed stem cell numbers by
ALDEFLUOR staining, an alternative marker of BCSCs (Ginestier
et al., 2007). As depletion of PRMT5 also reduced the proportion
of ALDEFLUOR+ T47D cells (Figure 1E), our data strongly imply
that PRMT5 is required for maintaining BCSC function in vitro.
Amplification and overexpression of PRMT5 in breast cancer
is associated with reduced patient survival rates (Figures S1D
and S1E) (Cerami et al., 2012; Gao et al., 2013; Gyo¨rffy et al.,
2010). Since chromatin-modifying enzymes are known to regu-
late cellular events that can lead to the conversion of non-
CSCs toward a CSC-like phenotype and the expansion of the
BCSC pool (Chang et al., 2011; Tam and Weinberg, 2013), we
next asked whether overexpression of active PRMT5 by co-ex-
pressing PRMT5 and its essential cofactor MEP50 was sufficient
to promote a BCSC phenotype. As expected, co-expression of
PRMT5 requires MEP50 for elevated symmetric dimethylation
levels (Figures 1F, S1F, and S1G). Accordingly, overexpression
of PRMT5 alone had no significant effect on primary mammo-
sphere numbers, whereas co-expression of PRMT5 and
MEP50 significantly increased both primary and secondary
mammosphere numbers (Figure 1G). Interestingly, co-overex-
pression of catalytically inactive PRMT5 (PRMT5-G367A/
R368A) (Pal et al., 2004) with MEP50 failed to stimulate BCSC
activity (Figures 1F and 1G). These findings therefore imply that
PRMT5 drives BCSC proliferation and self-renewal via the
methylation of target substrates.
PRMT5 Is Required for In Vivo BCSC Maintenance
The gold-standard in vivo assay to determine tumor-initiating
capacity of putative BCSCs is limiting dilution analysis. Here,
groups of NSG (NOD/Scid/IL-2Rgnull) mice were subcutane-
ously injected with five different dilutions (5 3 106 to 5 3 104)
of unsorted cells and monitored for tumor growth, the premise
being that the more tumor-initiating cells present within theFigure 2. PRMT5 Is Required for Maintenance of Stem Cells In Vivo
(A) Schematic of limiting dilution assay. MCF7 shCTRL or shPRMT5 cells were inj
were assessed by immunoblotting prior to the experiment (top).
(B) Stem cell frequencies of MCF7 shCTRL and shPRMT5 cells were determined
response (response = tumor > 0.1 cm3 at 20 days post-injection)/total number of t
cell frequency ± 95% confidence intervals.
(C) Mammosphere (MS) assays of tumor-derived cells from the indicated cell num
mean ± SEM.
(D) Dot density plot of final tumor weight. The bar represents mean. Table below
(E) Representative images of BrdU-stained tumor sections from shCTRL or shPR
(F) Immunoblot of PRMT5 in tumors derived from 5 3 105 shCTRL or shPRMT5-
(G) Stem cell frequencies of MCF7 CTRL or PRMT5/MEP50 cells were determine
response (response = tumor > 0.1 cm3 at 39 days post-injection)/total number of
confidence intervals.
(H) Mammosphere assay of cells isolated from CTRL and PRMT5/MEP50 tumor
Unless otherwise stated, all data are mean ± SEM, nR 3.
3502 Cell Reports 21, 3498–3513, December 19, 2017bulk tumor cell population, the fewer cells required to generate
a tumor (Figure 2A). After 20 days, control animals from the
53 106 cell group reached license limit, and all micewere scored
for the presence of tumors >0.1 cm3 as evidence of tumor initia-
tion. Depletion of PRMT5 clearly showed a reduction in the
potential to form tumors at all cell numbers injected, becoming
more evident with small cell numbers. For example, whereas 4
of 7 mice (57%) injected with 5 3 104 shCTRL cells developed
tumors, only 1 of 11 mice (9.1%) injected with the same number
of shPRMT5 cells did so. Strikingly, using L-Calc (Stem Cell
Technologies) to calculate stem cell frequency, we show that
depletion of PRMT5 reduced cancer stem cell numbers from
1:187,878 to 1:1,042,530, a 5.5-fold reduction (Figure 2B). In or-
der to determine the effects of PRMT5 depletion on BCSC and
tumor biology, mice in each group were aged and sacrificed
when control animals reached license limit. Tumors were
excised and analyzed for stem cell function by mammosphere
assay. Importantly, the reduction in stem cell frequency was
reflected ex vivo, as PRMT5-depleted cells from excised tumors
displayed reduced proliferation and self-renewal characteristics
(Figure 2C). Consistent with a reduction in stem cells, we
observed that PRMT5-depleted tumors were less proliferative,
as indicated by differences in final tumor weight, BrdU incorpo-
ration, and tumor growth rate (Figures 2D–2F and S2).
Conversely, overexpression of active PRMT5 in limiting dilution
xenografts increased stem cell numbers by 5.91-fold (Figures
2G, 2H, S3A, and S3B), which was reflected ex vivo by mammo-
sphere assay (Figure 2H). Together, this in vivo analysis clearly
shows that elevated levels of active PRMT5 are sufficient for
BCSC activity.
Although our limiting dilution analysis demonstrates an impor-
tant role for PRMT5 in regulating BCSCs, PRMT5 is also known
to promote the proliferation of bulk breast cancer cells (Fig-
ure S1A; Scoumanne et al., 2009). In line with this, depletion of
PRMT5 reduces both the in vitro and in vivo proliferation of
isolated BCSCs and the differentiated population (Figures
S3C–S3H). Importantly, and in agreement with our limiting dilu-
tion analysis using bulk cell population (Figures 2B and 2G),
depletion of PRMT5 affected the tumor-initiating capacity of
only ESA+CD24lowCD44+ BCSCs (Figure S3E), not the differenti-
ated population (Figure S3G). Taken together, these results
imply that PRMT5 has multiple roles in breast cancer growth,ected into NSG mice in a limiting dilution assay. PRMT5 levels of cells injected
using L-Calc software. Upper table shows number of tumors with a positive
umors and is depicted in the pie chart diagram below. Lower table shows stem
ber injected. For 53 106, error is mean ± range; for 53 105 and 53 104, error is
shows the average tumor weight ± SEM.
MT5-expressing cells. The scale bar represents 50 mm.
expressing cells (above). Images of resected tumors (below).
d using L-Calc software. Upper table shows number of tumors with a positive
tumors and is depicted below. Lower table shows stem cell frequency ± 95%
s.
regulating both tumor-initiating and more differentiated cells,
and that drug targeting of PRMT5 could potentially affect the sur-
vival of both cell populations.
To investigate the impact of PRMT5 depletion on tumor
biology, we performed histological analysis of excised tumors
in collaboration with a breast cancer pathologist and scored
for pathological features currently used in patient diagnosis.
We observed that PRMT5-depleted tumors displayed reduced
cellularity, increased fibrosis, and tubule formation, consistent
with a less aggressive phenotype (Figures 3A, 3B, and S4A).
Control tumors often exhibited high cellularity and large areas
of clear cell differentiation (Figure 3E), a phenotype of a particu-
larly aggressive breast cancer subtype. Areas of necrosis,
another feature of large, rapidly growing tumors, were also
observed in shCTRL tumors (Figures 3C and 3D). These features
were rarely exhibited in PRMT5-depleted tumors, correlating
with their small size. Interestingly, depletion of PRMT5 in AR or
ESA+CD24lowCD44+ populations did not alter cell cycle or pro-
mote apoptosis (Figures 3F and 3G). Hence, given that
PRMT5-depleted tumors appear more differentiated with a less
aggressive pathology, our findings are consistent with PRMT5
suppressing differentiation and thus facilitating the maintenance
of BCSC identity.
PRMT5 Is Required for BCSC Function in Established
Tumors
Recently, PRMT5 has become an attractive therapeutic target
for the treatment of leukemia and lymphoma, with pre-clinical
PRMT5-specific inhibitors displaying impressive in vivo efficacy
in murine models of mantle cell lymphoma and chronic myelog-
enous leukemia (CML) (Chan-Penebre et al., 2015; Jin et al.,
2016). However, these studies did not address the effect of
suppressing or inhibiting PRMT5 on tumor growth in an organism
that had already presented with disease, a critical question if
PRMT5 inhibitors are to be a viable therapeutic option. We there-
fore engineeredMCF7 cells to express a doxycycline (dox)-regu-
lated PRMT5 silencing construct (Tet-ON-shPRMT5) in combi-
nation with constitutive expression of the luciferase gene
enabling in vivo imaging of tumor growth (Figures 4A and 4B).
After subcutaneous injection, tumors were allowed to grow to
a palpable size (Figure S4B) and in vivo PRMT5 depletion
induced by feeding mice dox-supplemented chow (Figures 4A
and 4B). Tumors derived from Luc-Tet-ON-shCTRL cells
continued to grow for the duration of the experiment. In contrast,
in vivo depletion of PRMT5 substantially slowed tumor growth
and in some cases caused regression (Figures 4C and 4D).
Accordingly, Luc-Tet-ON-shPRMT5-derived tumors were
considerably smaller than control tumors (Figures 4E and 4F).
Although these results suggest that PRMT5 is required to
sustain the growth of an established carcinoma, we wanted to
determine if this was through the maintenance of the BCSC
population. We therefore serially transplanted cells derived
from Luc-Tet-ON-shCTRL and shPRMT5 tumors and conducted
limiting dilution analysis. Excised tumors were dissociated into
single cells, and five groups of NSG mice were subcutaneously
injected with 1 3 105 to 1 3 103 tumor-derived cells (Figure 5A).
PRMT5 silencing in the transplanted cells was validated by
immunoblotting, and tumors were allowed to develop for40 days. As expected, mice injected with larger numbers of cells
weremore likely to develop tumors than those injectedwith small
cell numbers (Figure 5C); however, irrespective of cell number,
PRMT5-depleted serially transplanted tumors grew at a much
slower rate (Figures 5B and 5D). Furthermore, examination of
the 13 103 cell group clearly demonstrated that whereas serially
transplanted Luc-Tet-ON-shCTRL-derived tumors steadily
outgrew, Luc-Tet-ON-shPRMT5-derived tumors cells failed to
generate any growths (Figure S4C). These findings strongly indi-
cate that in vivo depletion of PRMT5 alters the functional capac-
ity of tumor-initiating cells. Indeed, by scoring the number of
mice that presented with tumors >0.1 cm3 at time of collection
(all mice irrespective of group were collected at the same
time), Luc-Tet-ON-shPRMT5-derived, serially transplanted
tumors displayed a 12-fold reduction in stem cell frequency,
from 1:3,555 to 1:43,135, after in vivo PRMT5 depletion (Fig-
ure 5C). Consistent with a reduced tumorigenic capacity,
PRMT5-depleted xenografts were of a lower cellularity, dis-
played frequent tubule formation, and were sometimes highly
fibrotic, resulting in a greater proportion of tumors with a lower
histological grade (Figures 5E, S4D, and S4E). In support,
mammosphere analysis of resected and dissociated tumors
demonstrated that PRMT5 depletion reduced mammosphere-
forming capacity ex vivo (Figure 5F). Taken together, our data
are highly suggestive that depletion of PRMT5 in established car-
cinomas reduces tumor propagation by restricting the number of
BCSCs.
PRMT5 Epigenetically Regulates FOXP1 Expression
Because PRMT5 is an established regulator of gene expression
(Migliori et al., 2012; Zhao et al., 2009), we hypothesized that one
mechanism by which PRMT5 could be regulating BCSC function
was through transcriptional control. To investigate this, we iso-
lated three replicates of the ESA+CD24lowCD44+ populations
from MCF7-shCTRL and shPRMT5 cells and conducted RNA
sequencing (RNA-seq) to identify differences in gene expression.
Depletion of PRMT5 resulted in 214 significantly differentially
regulated genes, of which 136 were upregulated and 78 downre-
gulated (Figures S5A–S5C). KEGG pathway analysis of enriched
genes suppressed by PRMT5 (i.e., those that were upregulated
after shRNA depletion) identified cancer pathways and signaling
pathways (including cGMP-PGK, PI3K-AKT, ErbB, and FoxO
pathways) (Figure S5D), while metabolic genes are predomi-
nantly induced by PRMT5 (ALDOC,HK2, TSTA3, and ALDH3A1;
Figure S5E). Changes in expression of classic stem cell genes
such as OCT4 or NANOG were not detected by RNA-seq. How-
ever, closer examination by qPCR analysis of AR cells reconsti-
tuted with wild-type PRMT5 did imply that they were PRMT5
regulated (Figure S6A). Interestingly, Wnt/b-catenin genes, re-
ported as PRMT5 targets in leukemic stem cells (Jin et al.,
2016; Tee et al., 2010), could not be validated by qPCR
(Wnt5A, PRICKLE2), implying that the mechanisms by which
PRMT5 regulates stem cells in breast cancer and leukemia are
different.
Surprisingly, none of our top differentially expressed validated
genes appeared to have a close correlation with breast cancer
pathogenesis (Figures S5B and S5C), and although CDKN1A
was validated as a PRMT5-repressed gene (Figure S6B), theCell Reports 21, 3498–3513, December 19, 2017 3503
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Figure 3. Depletion of PRMT5 Reduces Tumor Aggressiveness but Does Not Affect Cell Cycle or Apoptosis
(A–E) Tumors were assessed for pathological features and are depicted in pie charts as indicated. Representative images of (A and B) cellularity, fibrosis, tubule
formation; (C and D) necrosis; and (E) clear cells. F, fibrous tissue; N, necrotic areas; T, tubule. The scale bar represents 100 mm.
(F) Cell cycle profiles of shCTRL or shPRMT5 AR cells.
(G) Annexin-FITC+ cells in ESA+CD24lowCD44+ cells, quantified (right). NS, not significant.
All data are mean ± SEM, nR 3.functional significance of this is unclear given that the cell cycle
profiles of shCTRL or PRMT5-depleted AR cells were indistin-
guishable (Figure 3F). We thus decided to focus our investiga-3504 Cell Reports 21, 3498–3513, December 19, 2017tions on FOXP1, a winged helix/forkhead transcription factor
that has been associated with normal and cancer stem cell
function (Choi et al., 2016; Gabut et al., 2011; Naudin et al.,
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Figure 4. In Vivo Depletion of PRMT5 Reduces Tumor Growth
(A) Immunoblot of PRMT5 in MCF7 Luc-Tet-ON-shCTRL and shPRMT5 cells ± 1 mg/mL doxycycline (dox) for 5 days.
(B) Schematic of study. Mice were injected with MCF7 cells expressing dox-inducible Luc-Tet-ON-shCTRL or shPRMT5. Tumors were allowed to develop, and
when palpable, mice were fed dox-supplemented chow to induce shRNA expression. Tumor growth was monitored by IVIS and caliper measurements.
(C) IVIS images of mice injected with Luc-Tet-ON shCTRL or shPRMT5 cells at times shown. Images were taken using the same exposure settings. Exposure
time = 1 s. (In some cases, mice were reimaged after unsuccessful luciferin injection. Images have been cropped accordingly [dotted white lines].)
(D) Growth of tumors before and after dox-supplemented diet.
(E) Image of resected tumors from Luc-Tet-ON shCTRL or shPRMT5 cells.
(F) Dot density plot of final tumor weight. The bar represents the mean.
All data are mean ± SEM, nR 3.2017). Intriguingly, FOXP1 is generally considered a tumor
suppressor in the breast because high levels correlate with bet-
ter prognosis, despite the finding that it promotes proliferation
and migration of breast cancer cell lines (Oskay Halacli, 2017;
Shigekawa et al., 2011; Xiao et al., 2016). Because of this
apparent contradiction and link with stem cell biology (Choiet al., 2016; Gabut et al., 2011), we decided to investigate the
relationship between PRMT5, FOXP1, and BCSC function in
more detail.
Similar to PRMT5, FOXP1 levels were significantly elevated in
AR cells (Figure 6A). Importantly, expression was PRMT5 depen-
dent, as depletion of PRMT5 decreased both protein (full-lengthCell Reports 21, 3498–3513, December 19, 2017 3505
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75 kDa FOXP1 isoform) and mRNA transcripts in AR and ESA+
CD24lowCD44+ cells (Figures 6B–6D). Moreover, FOXP1 expres-
sion was dependent on the catalytic activity of PRMT5 as recon-
stitution of PRMT5-depleted cells with ectopic wild-type but not
catalytically inactive PRMT5 increased FOXP1 transcripts (Fig-
ure 6C). We next wanted to determine if PRMT5 was directly
regulating FOXP1 expression. Using total cell population, we
used chromatin immunoprecipitation (ChIP) coupled to promoter
tiling to demonstrate an enrichment of PRMT5 at the FOXP1 pro-
moter. In comparison, PRMT5 was not recruited to the MYOD1
promoter, a muscle-specific gene regulated by PRMT5 but not
expressed in MCF7 cells (Dacwag et al., 2007) (Figures 6E and
S7A and S7B). Importantly, PRMT5 depletion significantly
reduced PRMT5 promoter occupancy (Figures 6E and S7B),
confirming that PRMT5 is truly recruited to the FOXP1 promoter
and validating specificity of our PRMT5 ChIP antibody. One
mechanism by which PRMT5 promotes gene expression is
through the methylation of H3R2 (H3R2me2s), which is recog-
nized by WDR5, enabling the recruitment of the SET1/MLL com-
plex and histone H3K4 trimethylation (H3K4me3) (Migliori et al.,
2012). Consistent with this chain of events, H3R2me2s, SET1,
and H3K4me3 were all enriched at the FOXP1 promoter in a
PRMT5-dependent manner (Figures 6F–6H and S7C–S7E).
Crucially, this observation was also true in the tumor-initiating
population, as treatment of AR cells with the PRMT5 inhibitor
GSK591 (Duncan et al., 2015) substantially reduced FOXP1 pro-
moter H3K4me3 levels (Figure 6I), and treatment of primary
mammospheres with the WDR5 antagonist OICR-9429 (Grebien
et al., 2015) reduced BCSC proliferation in a dose-dependent
manner (Figure S7G). Even though global levels of H3R2me2s
were not altered by PRMT5 depletion (Figure S7H), our findings
are highly supportive that PRMT5 is directly recruited to the
FOXP1 promoter, facilitating H3K4me3 and gene expression
via H3R2me2s.
Given that FOXP1 has been proposed to function as a tumor
suppressor in the breast, we wanted to determine the effect of
FOXP1 on MCF7 growth. In support of a pro-tumorigenic role,
FOXP1 depletion in MCF7 cells results in growth suppression,
whereas overexpression enhances growth (Figures 6J and 6K).
More significantly, depletion of FOXP1 in xenografts significantly
reduced tumor growth (Figures 6L and S7F). Indeed, transcript
levels of FOXP1 are elevated >11-fold in MCF7 cells compared
with immortalized but non-transformed mammary epithelial
MCF10A cells (Figure 6D). Next, we wanted to determine if
PRMT5-mediated upregulation of FOXP1 is required for BCSCFigure 5. In Vivo Depletion of PRMT5 Reduces Stem Cell Frequency
(A) Schematic of study. Following in vivo depletion of PRMT5, MCF7 Luc-Tet-O
resected tumors (C1-3 and P1-3 denote Luc-Tet-ON-shCTRL and PRMT5 tumors
in a limiting dilution assay. Tumor growth was monitored by IVIS and caliper me
(B) Tumor growth in mice injected with 1 3 105 cells (Gp1; solid line) or 5 3 103
(C) Stem cell frequencies of Luc-Tet-ON shCTRL and shPRMT5 cells were det
positive response (response = tumor > 0.1 cm3)/total number of tumors and is
intervals.
(D) IVIS images of mice injected with 1 3 105 tumor-derived Luc-Tet-ON shCTR
(E) Tumors were assessed for pathological features and depicted in pie charts a
tissue; T, tubule. The scale bar represents 100 mm.
(F) Dot density plot of mammosphere formation of tumor-derived cells. The bar r
All data are mean ± SEM, nR 3.function. Interestingly, FOXP1 depletion in MCF7 cells express-
ing endogenous levels of PRMT5/MEP50 reduced primary
mammosphere numbers but did not significantly affect second-
ary mammospheres (Figures 6M and 7B), implying that under
these conditions, FOXP1 regulates BCSC numbers and prolifer-
ation rather than self-renewal. In contrast, depletion of FOXP1 on
the background of ectopically expressed PRMT5 and MEP50
completely abrogated the effects of PRMT5 and MEP50 overex-
pression on both BCSC numbers and proliferation and self-
renewal (Figure 6M), implying that the effects of hyperactive
PRMT5 on BCSC proliferation and self-renewal are mediated
through FOXP1. These findings therefore suggest that a
threshold level of FOXP1 expression, presumably via PRMT5-
mediated epigenetic regulation, is required for self-renewal or
that high levels of an unknown FOXP1 cofactor that drives self-
renewal gene expression is present only under certain PRMT5
conditions.
Pharmacological Inhibition of PRMT5 Reduces BCSC
Numbers In Vitro
Because we demonstrated that the catalytic activity of PRMT5
was required for driving BCSC function and FOXP1 expression
(Figures 1G and 6C), we wanted to determine whether a small-
molecule inhibitor targeting PRMT5 could affect BCSC function.
We therefore treatedMCF7 cells with the validated PRMT5 inhib-
itor GSK3203591 (EPZ015866; herein referred to as GSK591)
(Figure 7A; Duncan et al., 2015). Similar to PRMT5 depletion,
inhibition of PRMT5 significantly suppressed MCF7-derived
BCSC proliferation and self-renewal and the number of
ALDEFLUOR+ T47D cells (Figures 7B and S7I), while over-
expression of FOXP1 was able to rescue the BCSC proliferative
defect induced by GSK591 (Figure 7C). Our data thus imply that
drug targeting PRMT5 reduces the activity of BCSCs, but given
that depletion of FOXP1 and GSK591 was not epistatic in
reducing primary and secondary mammospheres (Figure 7B),
FOXP1 is important but not sufficient for all PRMT5-dependent
events in BCSCs.
PRMT5 has been reported as a critical component of
normal stem cell function (Chittka et al., 2012; Liu et al.,
2015), hence one potential limitation of PRMT5-directed ther-
apies for breast cancer is the suppression of normal mammary
stem cell function. Interestingly, although knockdown and
inhibition of PRMT5 reduces the number of primary mam-
mospheres of MCF10A cells, self-renewal was unaffected
(Figures 7B, S7I, and S7J). In support, stem cell numbers,N-shCTRL and shPRMT5 tumors were harvested. Immunoblot of PRMT5 in
, respectively) that were dissociated into single cells and injected into NSGmice
asurements.
cells (Gp5; dashed line).
ermined using L-Calc software. Upper table shows number of tumors with a
depicted below. Lower table shows stem cell frequency ± 95% confidence
L or shPRMT5 cells at the specified time points.
s indicated. Representative images (right) of pathological features. F, fibrous
epresents the mean. Red, pool of two tumors; blue, pool of three tumors.
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as determined by ALDEFLUOR staining was unaffected by
GSK591 (Figure S7I). Moreover, this lack of effect of PRMT5
deletion or inhibition on MCF10A self-renewal was not due
to receptor status, as treatment of the triple-negative breast
cancer cells SUM159 with GSK591 phenocopies that of
MCF7 cells, reducing both BCSC proliferation and self-
renewal (Figure 7B). Hence, it appears that PRMT5 activity
specifically affects self-renewal of cancer rather than normal
mammary stem cells.
We next wanted to evaluate the ability of PRMT5 deple-
tion to synergize with conventional chemotherapy for ER+
tumors. Although PRMT5 depletion did not alter the ability
of 4-hydroxytamoxifen (4-OHT), the active metabolite of
tamoxifen, to suppress primary mammosphere numbers (Fig-
ure 7D), secondary mammosphere formation was markedly
reduced (Figure 7E). Thus, PRMT5 inhibitors in combina-
tion with 4-OHT appear to synergistically suppress BCSC
self-renewal.
To correlate our cell culture findings with therapeutic potential,
we isolated cancer cells from freshly resected ER+ patient-
derived tumors from a cohort that had not undergone neo-adju-
vant chemotherapy and conducted mammosphere analysis in
the presence of GSK591. Continuous treatment of patient-
derived BCSCs with GSK591 markedly suppressed mammo-
sphere formation, indicative that inhibition of PRMT5 is effec-
tively depleting primary-derived BCSCs (Figure 7F). Taken
together, our results strongly imply that therapeutic targeting of
PRMT5 could be an effective way of eradicating the cancer
stem cell compartment.
DISCUSSION
PRMT5 has been increasingly associated with maintaining
normal cell and leukemic cell ‘‘stemness’’ (Jin et al., 2016; Liu
et al., 2015; Tee et al., 2010; Zhang et al., 2015), but very little
is known about the role of PRMT5 in cancer stem cells driving
carcinoma formation. In this study, we confirm that PRMT5 reg-
ulates the proliferation of bulk breast cancer cells and, more
importantly, define a critical role for PRMT5 in the maintenance
and propagation of BCSCs in vitro and in vivo through the epige-
netic regulation of FOXP1. These findings are of high clinical
relevance because small-molecule inhibitors of PRMT5 are in
pre-clinical development, exhibiting good in vivo efficacy against
lymphomas and leukemia (Chan-Penebre et al., 2015; Jin et al.,
2016). Hence, drug targeting PRMT5 in the breast could have
a dual effect of not only targeting more differentiated cancerFigure 6. PRMT5 Epigenetically Regulates FOXP1 Expression
(A) FOXP1 (75 kDa isoform) and PRMT5 protein levels were assessed in the AR
(B) Immunoblot of FOXP1 levels in AR cells after PRMT5 depletion.
(C) FOXP1 expression was assessed by qPCR in AR cells isolated from MCF7 s
cells. Immunoblot of PRMT5 (below).
(D) PRMT5 and FOXP1 transcript levels were assessed in MCF7 or MCF10A cel
(E–H) Enrichment of (E) PRMT5, (F) H3R2me2s, (G) SET1, and (H) H3K4me3 or r
(I) H3K4me3 enrichment at the FOXP1 promoter in AR cells ± GSK591.
(J and K) Growth curve of MCF7 cells after (J) FOXP1 depletion or (K) FOXP1 ov
(L) Average weight of shCTRL or shFOXP1 tumors. Images of resected tumors (b
(M) Mammosphere assay of FOXP1-depleted cells overexpressing PRMT5 and M
All data are mean ± SEM, nR 3.cells but also effectively eliminating the tumor-initiating/BCSC
population.
One key observation in this study is that PRMT5 depletion
in established tumors, thereby mimicking a patient present-
ing with disease, substantially decreases BCSC frequency,
implying that PRMT5 inhibitors could potentially eradicate
this population to prevent relapse. Indeed, our data showing
that treatment of patient-derived BCSCs with the tool
PRMT5 inhibitor GSK591 decreases BCSC frequency and
proliferation represent, to our knowledge, the first account of
a PRMT5 inhibitor influencing cancer stem cells derived from
solid cancers. One concern with epigenetic-based therapies
is that many chromatin remodeling enzymes are essential for
normal homeostatic function. Indeed, PRMT5 is an essential
gene with deletion causing early embryonic lethality in mice
(Tee et al., 2010). Surprisingly, we found that although
PRMT5 depletion or inhibition did affect the proliferation of
the non-transformed mammary epithelial cell line, MCF10A,
self-renewal was unaffected, implying that either PRMT5 is
not required for self-renewal of normal mammary stem cells
or that residual methyltransferase activity after knockdown
or inhibition is sufficient to maintain normal function. Indeed,
PRMT5 expression levels are elevated in BCSCs compared
with normal mammary stem cells (Figure 6D), implying that
BCSCs are potentially more dependent on PRMT5 activity.
Similarly, leukemic CML CD34+ cells have elevated PRMT5
expression compared with normal bone marrow CD34+ cells,
and PRMT5 inhibition only affects the self-renewal of leukemic
CD34+ stem cells (Jin et al., 2016). Together, our results in
conjunction with others imply that elevated PRMT5 expression
within cancer stem cells offers a therapeutic window for drug
treatment.
We identify that one mechanism by which PRMT5 regulates
BCSCs is via the epigenetic regulation of FOXP1. PRMT5
is recruited to the FOXP1 promoter, leading to H3R2me2s,
SET1 binding, and H3K4me3. Interestingly, although PRMT5-
dependent H3K4me3 is a common mechanism for gene regu-
lation in both leukemic and BCSCs, the genes that are targeted
appear to be specific to the origin of the cancer stem cell,
implying that the cellular mechanisms by which stemness is
maintained by PRMT5 are distinct. Our results clearly show
that FOXP1 is an important target of PRMT5, as overexpression
can rescue the BCSC proliferation defect induced by GSK591,
whereas knockdown decreases BCSC proliferation and self-
renewal induced by hyperactive PRMT5. However, depletion
of FOXP1 and PRMT5 inhibition are not epistatic for primarypopulation in MCF7 cells and quantified below.
hCTRL, shPRMT5, and shPRMT5 + PRMT5 (WT)/PRMT5 G367A/R368A (MD)
ls after PRMT5 depletion.
abbit IgG at the FOXP1 promoter was assessed by ChIP-qPCR.
erexpression.
elow).
EP50. Immunoblot of FOXP1 (right).
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Figure 7. Inhibition of PRMT5 Reduces Self-
Renewal in Cancer Cells and Sensitizes
Mammospheres to 4-OHT Treatment
(A) Inhibition of PRMT5 activity using GSK591 was
shown by immunoblotting for pan-symmetric di-
methylarginine (SDMA). SmD3, a known target of
PRMT5 was used as a loading control.
(B) Mammosphere assay of MCF7 shCTRL or
shFOXP1, SUM159 (triple negative), and MCF10A
cells treated with 5 mM GSK591 or DMSO (vehicle
control).
(C) Mammosphere assay of MCF7 cells over-
expressing FOXP1 ± 5mM GSK591.
(D) Primary mammosphere assay of MCF7
shCTRL or shPRMT5 cells ± 2.5 mM 4-OHT.
(E) Primary mammospheres from (D) were disso-
ciated and replated. Secondary mammospheres
were scored.
(F) Schematic of experiment. Patient-derived
tumors were dissociated into single cells. Mam-
mosphere assay of tumor-derived cells ± 5mM
GSK591 (right). Representative images of mam-
mospheres are shown.
All data are mean ± SEM, nR 3.and secondary mammosphere formation (Figure 7B), indicating
that although FOXP1 is important, it is not the sole PRMT5
effector. Indeed, given that more than 200 genes are signifi-
cantly deregulated after PRMT5 depletion, it would be inter-
esting to understand which of these genes are direct epigenetic
targets of PRMT5 and which are regulated downstream of
FOXP1.
To date, immunohistochemical analysis has suggested that
FOXP1 functions as a breast cancer tumor suppressor gene,
as low levels correlate with poor prognosis (Xiao et al., 2016).
In contrast, our findings clearly show that FOXP1 is pro-onco-
genic, promoting breast cancer cell proliferation and in vivo tu-
mor growth. One reason for the apparent discrepancy is that
interpretation of FOXP1 immunohistochemistry is challenging.
At least seven isoforms of FOXP1 are expressed, which are all3510 Cell Reports 21, 3498–3513, December 19, 2017detected by the JC12 antibody (Brown
et al., 2008). Given that some isoforms
are known to be more oncogenic (Choi
et al., 2016; Gabut et al., 2011) or pro-
mote stem cell function (Gabut et al.,
2011), our results highlight the necessity
of understanding the pathological role of
a protein before the significance of clin-
ical correlations is made. Indeed, our ob-
servations that FOXP1 contributes to
BCSC function build upon a growing
connection between FOXP1 and normal
and cancer stem cell biology (Gabut
et al., 2011; Choi et al., 2016; Naudin
et al., 2017). Interestingly, in ESCs,
a switch in FOXP1 isoform usage is
responsible for pluripotent gene induc-
tion while concurrently repressing differ-
entiation genes (Gabut et al., 2011). Thisis intriguing because PRMT5 is a major regulator of alternative
splicing events (Bezzi et al., 2013). Analysis of MDM4 splicing
failed to detect expression of the splice isoform MDM4S (Fig-
ure S6C), and our RNA-seq analysis was not at sufficient read
depth to detect alterations in splicing patterns, but it would be
important to fully explore whether in addition to directly regu-
lating FOXP1 transcription, PRMT5 might also direct FOXP1
alternative splicing and isoform use.
In summary, our findings reveal important insights that link
arginine methylation to the maintenance of the tumor-initiating
BCSC population. Given the development of pre-clinical small
molecules targeting PRMT5, combination treatment of PRMT5
inhibitors, along with conventional chemotherapy enabling tu-
mor de-bulking, could have a significant impact on long-term
outcomes for breast cancer patients.
EXPERIMENTAL PROCEDURES
Isolation of Stem Cell-Enriched Populations
BCSCs were isolated by either flow cytometry sorting of ESA+CD24lowCD44+
MCF7 cells or by isolation of AR cells using the Miltenyi Dead Cell
Removal kit. For further details, see Supplemental Experimental Procedures.
Generation of Stable Cell Lines
Cell lines stably expressing shRNA sequences were generated by transducing
with lentiviral supernatant containing 8 mg/mL polybrene (Sigma-Aldrich) by
centrifugation for 90 min at 4,000 rpm. See Supplemental Experimental Pro-
cedures for more details and shRNA sequences.
Mammosphere Assay
MCF7, T47D, and MCF10A cells were plated onto pHEMA (Sigma-Aldrich)-
coated six-well plates and cultured at 37C for 5 days. Mammospheres
>50 mm were scored using a graticle. For serial replating, mammospheres
were disaggregated and cultured for a further 5 days prior to scoring. For
drug treatment, cells were incubated with 5 mM GSK591 or 2.5 mM 4-OHT
(Sigma-Aldrich) or vehicle controls. For further details, see Supplemental
Experimental Procedures.
Xenograft Studies and In Vivo Imaging
Animal experiments were conducted in accordance with United Kingdom
Home Office regulations. For the limiting dilution assay, 5- to 7-week-old fe-
male NSG mice were injected with the appropriate number of cells and a
slow release estrogen pellet (NE-121; Innovative Research of America) was
subcutaneously implanted at the base of the tail. Two hours prior to harvest
at the experimental endpoint, mice were injected with 100 mg/kg BrdU
(Sigma-Aldrich). For in vivo depletion of PRMT5, female NSG mice were in-
jected with 5 3 106 cells and once tumors were palpable, maintained on a
diet of dox chow (T-5BQ8-1816629-203; TestDiet). For imaging, mice were in-
jected intraperitoneally (i.p.) with 150mg/kg of luciferin (Promega), and images
were captured on an IVIS Spectrum. See Supplemental Experimental Proced-
ures for more detail.
RNA Sequencing
Three independent replicates of ESA+CD24lowCD44+ cells were isolated by
flow cytometry from MCF7 shCTRL or shPRMT5 cells. Total RNA was ex-
tracted and rRNA was depleted prior to sequencing on the Illumina Hiseq.
Sequenced reads were mapped to build hg19 of the human genome from
the University of California, Santa Cruz (UCSC) genome database. Differential
gene expression was determined using Cuffdiff 2.2.1 with a threshold of false
discovery rate (FDR) <0.05 and fold change >1.5. Enriched Gene Ontology
terms and KEGG pathways were identified using DAVID (https://david.
ncifcrf.gov) (Huang et al., 2009). For more detail, see Supplemental Experi-
mental Procedures.
ChIP
Chromatin extraction and ChIP were performed as described previously
(Clarke et al., 2017). Briefly, cells were fixed, lysed, and sonicated to produce
DNA fragments of between 300 and 500 bp. Chromatin was precleared and
ChIP was performed using chromatin equivalent to 5 3 106 cells. Chromatin
was incubated overnight at 4C with antibody followed by 3 hr incubation
with protein G beads. Immunoprecipitated DNA was reverse crosslinked
and treatedwith proteinase-K. DNAwas isolated by phenol/chloroform extrac-
tion and ethanol precipitation. For ChIP of AR cells, cells were treated for
5 days with 5 mM GSK591 prior to replating overnight in suspension. AR cells
were isolated using the Miltenyi Dead Cell Removal kit. Following isolation,
cells were processed as above. For more detail, see Supplemental Experi-
mental Procedures.
Statistical Analysis
Unless otherwise stated, error bars represent mean ± SEM, nR 3 animals or
experimental repeats. All statistical analysis was carried out using Student’s
t test (*p < 0.05, **p < 0.001, *** p < 0.005).DATA AND SOFTWARE AVAILABILITY
Original scans of all immunoblots presented in this manuscript can be found
at https://data.mendeley.com/datasets/h4y9yxzk3k/draft?a=d426c8ce-edd6-
4a3a-9d7f-1e0aac13565a.
The accession number for the RNA-seq data reported in this paper is GEO:
GSE107762.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2017.11.096.
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